This study evaluated the efficacy, safety, and cost of minocycline, ornidazole, esomeprazole, and bismuth (MOEB) therapy versus classical therapy (amoxicillin, clarithromycin, esomeprazole, and bismuth potassium citrate, ACEB) for Helicobacter pylori eradication. In a randomized trial of 390 patients, MOEB demonstrated superior eradication rates (93.2% per-protocol, 78.5% intention-to-treat) compared to ACEB (82.5% per-protocol, 72.8% intention-to-treat). Adverse events were significantly lower with MOEB (19.3% vs. 33.8%, p = 0.0019). MOEB was also more cost-effective, with a direct cost of 675.7 CNY versus 970.1 CNY for ACEB, yielding an incremental cost-effectiveness ratio of -27.5 CNY per eradication rate. MOEB is a safe, effective, and cost-efficient first-line regimen for H. pylori eradication.

Background and aim: Efficacy of Helicobacter pylori (H. pylori) eradication is related to the local antimicrobial resistance epidemiology. We aimed to investigate the antibiotic resistance of H. pylori in Fujian, China.Methods: H. pylori-infected patients in four centers were enrolled in the study from Oct 2019 to Jan 2022. The bacteria were isolated, cultured and identified from the biopsy of patients' gastric mucosa samples. Antimicrobial susceptibility testing was performed by a modified broth microdilution method for H. pylori to seven guideline-recommended antibiotics and seven potential choices for H. pylori eradication.Results: A total of 205 H. pylori strains were isolated. The resistance rates of amoxicillin (AMX), amoxicillin and clavulanate potassium (AMC), cefixime (CFM), gentamicin (GEN), tetracycline (TET), doxycycline (DOX), azithromycin (AZM), clarithromycin (CLR), levofloxacin (LVFX), sparfloxacin (SPFX), metronidazole (MTZ), tinidazole (TID), rifampicin (RFP) and furazolidone (FZD) were 11.22%, 12.20%, 7.32%, 12.20%, 4.88%, 4.39%, 44.39%, 43.90%, 30.24%, 21.46%, 40.98%, 45.85%, 5.37% and 10.24%, respectively. The rates of pan-sensitivity, single, double, triple and multiple resistance for seven guideline-recommended antibiotics were 32.68%, 30.24%, 13.17%, 7.76%, and 14.15%, respectively. The main double-resistance patterns were CLR+MTZ (10/205, 5%) and CLR+LVFX (9/205, 4%). The main triple-resistance pattern was CLR+MTZ+ LVFX (15/205, 7%).Conclusions: In Fujian, the prevalence of H. pylori resistance to AZM, CLR, LVFX, SPFX, MTZ, and TID was high, whereas that to AMX, AMC, GEN, CFM, TET, DOX, RFP and FZD was relatively low. CFM and DOX are promising new choices for H. pylori eradication.

目的 探讨内镜黏膜下剥离术(Endoscopic submucosal dissection,ESD)治疗表浅食管癌及癌前病变的疗效,分析影响其预后的相关因素.方法 选择 2010 年 10 月至 2022 年 10 月在本院诊治的表浅食管癌及癌前病变患者 65 例,按治疗方式将其分为ESD组 40 例,外科手术组 25 例,比较两种方法的安全性、有效性.根据患者预后分为存活组 60 和死亡组 5 例,分析影响其预后的相关因素.结果 ESD组治愈性切除率(95.56%)与外科手术组(95.00%)差异无统计学意义(P>0.05);ESD组术中出血量显著降低(P<0.05);术后住院时间明显短于外科手术组,差异有统计学意义(P<0.05);术后并发症率为 5.00%显著低于外科手术组 36.00%(P<0.05);存活组与死亡组在性别、年龄、是否吸烟、是否饮酒、手术操作时间是否>90 min方面差异无统计学意义(P>0.05);发生并发症人数显著低于死亡组(P<0.05);多因素Logistic分析结果显示病理为早期食管癌、病变合并溃疡、术后出现食管反流是影响表浅食管癌及癌前病变预后的独立危险因素.结论 ESD治疗表浅食管癌及癌前病变效果及安全性不亚于外科手术,且合并溃疡、病理为早期食管癌、食管反流是影响表浅食管癌及癌前病变预后的独立危险因素.

目的 探讨如何选择大肠有蒂大息肉圈套电切除方式.方法 回顾性分析2016年1月-2020年1月246例(259枚息肉)在厦门市中医院行大肠有蒂大息肉(直径≥1.0 cm)圈套电切除治疗患者的内镜和病理资料,统计内镜下黏膜切除术(EMR)组、钛夹组和尼龙绳组内镜下治疗操作成功率、息肉整块切除率、完整切除率、治愈性切除率和并发症发生率.结果 有蒂大息肉中,腺瘤性息肉形态改变86.89％(179/206)高于非腺瘤性息肉的28.30％(15/53)(P<0.01).尼龙绳组息肉直径最大(2.13±0.70)cm,钛夹组(1.51±0.44)cm,EMR组最小(1.31±0.31)cm,3组比较,差异有统计学意义(P<0.05).尼龙绳组癌变率为46.15％(24/52),高于EMR组的17.24％(25/145)(P<0.01).圈套电切除息肉完整切除率、整块切除率均为100.00％,治愈性切除率为98.46％(255/259),出血率为7.34％(19/259),穿孔率为0.00％(0/259).EMR组操作成功率和治愈性切除率均为100.00％(145/145),钛夹组分别为98.39％(61/62)和100.00％(62/62),尼龙绳组均为92.31％(48/52).EMR组出血率、术中出血率和术后出血率分别为10.34％(15/145)、8.97％(13/145)和2.07％(3/145),钛夹组分别为1.61％(1/62)、0.00％(0/62)和1.61％(1/62),尼龙绳组分别为5.77％(3/52)、3.85％(2/52)和1.92％(1/52),钛夹/尼龙绳预防性蒂部结扎分别为3.51％(4/114)、1.75％(2/114)和1.75％(2/114).结论 ≥1.0 cm的有蒂息肉直径越大、癌变率越高.临床上可根据息肉直径不同采用EMR法、钛夹或尼龙绳法,钛夹/尼龙绳预防性蒂部结扎对预防出血有一定的作用.

AimTo determine the minimum inhibitory concentrations (MICs) of commonly used antibiotics against Helicobacter Pylori (H. pylori) in South China and compare their resistance rates by using EUCAST breakpoints and other breakpoints.MethodsPatients who had not previously received H. pylori treatment in clinical centers in South China were enrolled in this study from 2017 to 2020. Gastric biopsies were obtained for H. pylori culture. The MICs of amoxicillin (AMX), clarithromycin (CLA), metronidazole (MTZ), levofloxacin (LEV), tetracycline (TET) and furazolidone (FZD) were tested by broth microdilution method and assessed by two different breakpoints. ATCC43504 standard strain served as a control.ResultsA total of 208 H. pylori strains were isolated from patients' biopsy samples. The MICs of AMX, CLA, MTZ, LEV, TET and FZD for H. pylori were 0.0156-256mg/L (MIC50 0.125mg/L, MIC90 4mg/L), 0.0156- >256 mg/L (MIC50 0.0312mg/L, MIC90 64mg/L), 0.0156- >256mg/L (MIC50 8mg/L, MIC90 256mg/L), 0.0156-256mg/L (MIC50 0.25mg/L, MIC90 16mg/L), 0.0156-256mg/L (MIC50 0.0625mg/L, MIC90 4mg/L), and 0.0156- >256mg/L (MIC50 0.0312mg/L, MIC90 2mg/L), respectively. The MICs of AMX, CLA, MTZ, LEV, TET and FZD for ATCC43504 strain were 0.25mg/L, 0.0625mg/L, 64mg/L, 0.5mg/L, 1mg/L and 0.25mg/L, respectively. The resistance rate of FZD was 11.05%. The overall resistance rates according to EUCAST breakpoints and other breakpoints were 57.21% and 14.90% for AMX (p<0.001), 38.94% and 38.94% for CLA (p = 1), 39.42% and 50.96% for MTZ (p<0.001), 12.98% and 10.58% for TET (p = 0.025), 35.10% and 35.10% for LEV (p = 1), respectively.ConclusionsOur results demonstrate that AMX, FZD, and TET, but not MTZ, CLR or LEV, showed good anti-H. pylori activity in vitro in South China. When different breakpoints were used, similar results were found with CLA, and LEV, but not with AMX, MTZ, or TET.